Belgian researchers say AI could improve accuracy of diagnosing lung disease

Researchers at the University of Leuven in Belgium said a study they conducted showed artificial intelligence could help interpret, and thereby improve, lung function tests used to diagnose long-term lung disease.

Results of the study were presented Monday at the European Respiratory Society's International Congress.

As part of the study, the researchers used data from 968 people who were undergoing complete lung function testing for the first time.

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

Using a concept called “machine learning”, they developed an algorithm that takes into account  routine lung function parameters and clinical variables of smoking history, body mass index, and age to make a suggestion for the most likely diagnosis.

"We have demonstrated that artificial intelligence can provide us with a more accurate diagnosis in this new study,” Wim Janssens, senior author of the study, said. “The beauty of our development is that the algorithm can simulate the complex reasoning that a clinician uses to give their diagnosis, but in a more standardized and objective way so it removes any bias. "

Currently, clinicians rely on sifting through results using population-based parameters. By employing AI, the machine can observe a combination of patterns at one time to help produce a more accurate diagnosis.

Last week, Houston Methodist researchers announced they’re using artificial intelligence to quickly and accurately interpret patient charts to help physicians predict breast cancer risk, which they hope reduces unnecessary testing procedures performed as a result of false-positive mammograms.

- check out the release

Related Articles:
Houston Methodist team uses artificial intelligence to predict breast cancer risk 
Artificial intelligence tops Google VC's list of high-potential life sci techs 
EC adds Cellnovo to R&D project to add artificial intelligence in Type 1 diabetes management

Suggested Articles

Bio-Rad Laboratories received FDA clearance for two digital PCR products designed to monitor CML patients’ molecular responses to treatment.

Neuspera Medical raised a total of $26 million through the second tranche of a series B round, to fund clinical testing programs for its implants.

Voyager stands to receive up to $728 million in milestones for each compound AbbVie chooses to advance beyond phase 1.